Bortezomib in multiple myeloma: treatment response and survival outcome

Bassiony, Eslam S.M; Barakat, Ashraf F.; Ghannam, Amr Abd El-Aziz; Abozena, Essam A

doi:10.4103/tmj.tmj_21_17

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, the median age was 57 years (range 35-78 years). Our data was similar to other Egyptian studies conducted by Bassiony et al where the median age of the patients was ±60 years (range, 48-70 years) [12] and by Abdel Karim et al where the mean age of the patients of 59 years, range (37-74 years) [13].…”

Section: Resultssupporting

confidence: 91%

Multiple Myeloma: an 11-year of Experience in South Egypt Cancer Institute

2021

SECI Oncology Journal

View full text Add to dashboard Cite

Background and objectives: Multiple myeloma (MM) is a malignant neoplasm of plasma cells accounting for approximately 10% of all hematologic cancers. The rates of MM vary among different populations and findings on racial differences in survival in MM have been inconclusive. Our aim is to investigate the demographic data with reviewing the different lines of treatment and to assess the outcome and survival of the patients treated from MM at a single institution over an 11-year period. Methods: This retrospective study involved 70 patients with MM who were treated from January 1, 2008 to December 31, 2018 in the Medical Oncology Department at the South Egypt Cancer Institute (SECI). Results: The median age of patients was 57 years. The most presenting symptoms were bone pain which occurred in 90% of patients followed by anemia, hypercalcemia and renal impairment which occurred in 64%, 27% and 21% of patients respectively. Patients who received bortezomib based regimens had higher median progression free survival (PFS) and overall survival (OS) compared with conventional treatment as the median PFS was 30 months (P=0.051) while OS was 37 months (P=0.011) in patients received bortezomib based regimens. Conclusions: Multiple Myeloma in Egyptian patients is more common in younger age. Bortezomib based regimen gives survival outcome better than conventional treatment.

show abstract

Section: Resultssupporting

confidence: 91%

Multiple Myeloma: an 11-year of Experience in South Egypt Cancer Institute

2021

SECI Oncology Journal

View full text Add to dashboard Cite

show abstract

“…In this study, therapy was stopped or changed because of toxicity or treatment failure. Most studies worldwide indicate similarities with this study and concur that the Bortezomib regimen has a better therapeutic outcome [40,[42][43][44].…”

Section: Treatment Responsesupporting

confidence: 83%

“…Hemodialysis was performed on some patients who had evidence of renal damage, and aspirin was provided to all patients receiving immunomodulatory drugs unless contraindicated. Even though these results across the treatment groups are not statistically significant, similar reports have been observed in many sub-Saharan countries and other parts of the world [8,15,34,42].…”

Section: Ethical Considerationsupporting

confidence: 67%

Untitled

2024

Int J Blood Res Disord

View full text Add to dashboard Cite

Background: Multiple myeloma is a potentially fatal hematological malignancy characterized by clonal growth of terminally differentiated B cells. The development of novel medicines (proteasome inhibitors, immunomodulatory medications, antibodies targeting cell surface molecules, and autologous stem cell transplantation) has improved patients' quality of life and overall survival rate with multiple myeloma. Despite the advancement of these new therapies that help resolve disease progression and hence provide remission during the induction phase, some patients still relapse, and others die from the disease itself or treatmentrelated complications. Tanzania started treating patients with multiple myeloma using Melphalan and Prednisolone drug combinations more than 20 years ago. In 2017, a newer management protocol was implemented using MPT (Melphalan, Prednisolone, and thalidomide) and BTD (bortezomib, thalidomide, and dexamethasone) drug combinations. We have never evaluated our patient's responses and complications associated with using these drug combinations.Objective: To determine the complications and response to treatment regimens among multiple myeloma patients attended at Muhimbili National Hospital. Study population and methodology:A retrospective cohort study was carried out among patients diagnosed with multiple myeloma and managed at MNH from January 2017 to December 2020. A total of 177 medical records of patients from the registry of hematology patients at the medical record department of MNH and the Jeeva system were reviewed and analyzed. A systematic questionnaire was utilized to collect socio-demographic and clinical data. SPSS version 23 was used to perform statistical analysis on the data. P-values of less than 0.05 were considered statistically significant. To compare categorical data, Fisher's exact test was used. Continuous variables were analyzed using ANOVA for mean values and the Kruskal Wallis test for the median.

show abstract

Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature

Vora

Patel

Dharamsi

2020

PRA

View full text Add to dashboard Cite

Background: Bortezomib is reversible inhibitor of proteasome proteins for mammalian cells. Bortezomib is proven to be cytotoxic to a number of tumor cells by disrupting their normal homeostatic mechanism and thereby causing cell death. Currently, Bortezomib is prescribed for patients with multiple myeloma and mantle cell lymphoma. Objective: This assessment highlights the overview of recent patents of Bortezomib. This review includes patents grouped in sections like product patents, process patent, composition related patents as well as treatment methodology. Objective of this article is to facilitate researchers with all existing patents at single place. Methods: Data were searched from various online databases. In which, paid databases include SciFinder® and Orbit® . Free databases include Patentscope® (WIPO), Worldwide Espacenet® (EPO), Google Patents and InPASS (Indian patent database). Results: Several new processes and composition related patents of Bortezomib have been recently patented as its orangebook listed patents are going to soon expire during July 2022. Further, due to problem of oxidation during development and long-term storage of Bortezomib formulation, a number of excipients are tried in these patents to stabilize the same. However, there is still need for further development of improved formulation of Bortezomib with better characteristics. Conclusion: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices.

show abstract

Bortezomib in multiple myeloma: treatment response and survival outcome

Cited by 3 publications

References 0 publications

Multiple Myeloma: an 11-year of Experience in South Egypt Cancer Institute

Multiple Myeloma: an 11-year of Experience in South Egypt Cancer Institute

Untitled

Bortezomib – First Therapeutic Proteasome Inhibitor for Cancer Therapy: A Review of Patent Literature

Contact Info

Product

Resources

About